Japanese approvals include Prograf for ulcerative colitis
This article was originally published in Scrip
Executive Summary
Astellas's Prograf (tacrolimus) has been approved in Japan for the treatment of ulcerative colitis, the fifth indication for the immunosuppressant in the company's home market.